Is dyslipidemia associated with a decline in kidney function?
A number of observational studies have demonstrated an association between dyslipidemia and a higher risk of kidney function decline.
Post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial showed that in persons with type 2 diabetes, proteinuria of at least 300 mg/day and at least CKD stage 3, higher total, and LDL cholesterol at baseline was associated with an increased risk of end-stage kidney disease (ESKD).
Low HDL cholesterol and high triglyceride levels in the setting of even mild to moderate CKD were also associated with a decline in kidney function. In addition, among diabetics without kidney disease, the presence of high total cholesterol was associated with an increased risk of developing albuminuria.
